Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, ITT, day 28 30% Improvement Relative Risk Mortality, PP, day 28 38% Mortality, ITT, day 14 61% Mortality, PP, day 14 65% c19early.org/d Annweiler et al. NCT04344041 COVIT-TRIAL Vitamin D RCT EARLY Is early treatment with vitamin D beneficial for COVID-19? RCT 254 patients in France Lower mortality with vitamin D (not stat. sig., p=0.29) Annweiler et al., PLoS Medicine, doi:10.1371/journal.pmed.1003999 Favors high dose Favors low dose
High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial
Annweiler et al., PLoS Medicine, doi:10.1371/journal.pmed.1003999, COVIT-TRIAL, NCT04344041 (history)
Annweiler et al., High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A.., PLoS Medicine, doi:10.1371/journal.pmed.1003999, COVIT-TRIAL, NCT04344041
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT comparing single dose 400,000IU and single dose 50,000IU vitamin D in France, showing lower mortality with the higher dose, statistically significant only at day 14.
The aHR for days 0-5 was 1.30 [0.31-5.35], compared to 0.11 [0.02-0.52] for days 6-14, which in part may reflect the conversion delay for cholecalciferol treatment. The lower efficacy at day 28 vs. day 14 may in part reflect use of only a single dose.
risk of death, 30.0% lower, HR 0.70, p = 0.29, treatment 19 of 126 (15.1%), control 21 of 126 (16.7%), Cox proportional hazards, day 28, intention-to-treat.
risk of death, 38.0% lower, HR 0.62, p = 0.17, treatment 17 of 121 (14.0%), control 21 of 121 (17.4%), Cox proportional hazards, day 28, per-protocol.
risk of death, 61.0% lower, HR 0.39, p = 0.049, treatment 8 of 127 (6.3%), control 14 of 127 (11.0%), Cox proportional hazards, day 14, intention-to-treat.
risk of death, 65.0% lower, HR 0.35, p = 0.03, treatment 7 of 122 (5.7%), control 14 of 122 (11.5%), Cox proportional hazards, day 14, per-protocol.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Annweiler et al., 31 May 2022, Randomized Controlled Trial, France, peer-reviewed, 17 authors, dosage 400,000IU single dose, trial NCT04344041 (history) (COVIT-TRIAL).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: PLOS MEDICINE RESEARCH ARTICLE High-dose versus standard-dose vitamin D supplementation in older adults with COVID19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Annweiler C, Beaudenon M, Gautier J, Gonsard J, Boucher S, Chapelet G, et al. (2022) High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial. PLoS Med 19(5): e1003999. https://doi.org/10.1371/journal. pmed.1003999 Academic Editor: Suzanne C. Cannegieter, Leiden University Medical Center, NETHERLANDS Received: July 12, 2021 Cédric Annweiler ID1*, Mélinda Beaudenon ID1, Jennifer Gautier ID1, Justine Gonsard2, Sophie Boucher ID3, Guillaume Chapelet4, Astrid Darsonval5, Bertrand Fougère6, Olivier Guérin7, Marjorie Houvet8, Pierre Ménager9, Claire Roubaud-Baudron ID10, Achille Tchalla11, Jean-Claude Souberbielle12, Jérémie Riou ID2, Elsa Parot-Schinkel2, Thomas Célarier13, on behalf of the COVIT-TRIAL study group¶ 1 Department of Geriatric Medicine and Memory Clinic, Research Centre on Autonomy and Longevity, University Hospital, Angers, France; UNIV Angers, UPRES EA 4638, University of Angers, Angers, France, 2 Delegation for Clinical Research and Innovation, Angers University Hospital, Angers, France, 3 Department of ENT Head and Neck Surgery, University Hospital, Angers, France; MitoLab Team Mitochondrial Medecine Research Centre, MitoVasc Intitute, UNIV Angers, CNRS UMR6015, INSERM U1083, University of Angers, Angers, France, 4 Department of Geriatric Medicine and Memory Clinic, Research Centre, University Hospital, Nantes, France; Inserm UMR1235, Nantes Université, Nantes, France, 5 Department of Pharmacy, Angers University Hospital, Angers, France, 6 Division of Geriatric Medicine, Tours University Hospital, Tours, France; Education, Ethics, Health (EA 7505), Tours University, Tours, France, 7 Université Côte d’Azur, Centre Hospitalier Universitaire de Nice, Service de Médecine Gériatrique et Thérapeutique, Nice, France; Université Côte d’Azur, CNRS UMR 7284/INSERM U108, Institute for Research on Cancer and Aging Nice (IRCAN), Faculté de Médecine, Nice, France, 8 Department of Geriatric Medicine, General Hospital, Saumur, France, 9 Department of Geriatric Medicine, General Hospital, Le Mans, France, 10 Pôle de Gérontologie Clinique, CHU Bordeaux, Bordeaux, France; INSERM 1053, Univ. Bordeaux, Bordeaux, France, 11 Unité de Recherche Clinique et d’Innovation (URCI) de Gérontologie, Pôle HU Gérontologie Clinique, CHU de Limoges, France; Université de Limoges, IFR GEIST, Laboratoire UR Vie-Santé (Aging and Digital health Lab) Faculté de Medicine de Limoges, Limoges, France, 12 Service des Explorations Fonctionnelles, Hôpital Necker-Enfants Malades, AP-HP, Paris, France, 13 Department of Clinical Gerontology, University Hospital of Saint-Etienne, SaintEtienne, France; Chaire Santé des Ainés, University of Jean Monnet, Saint-Etienne, France ¶ Membership of the COVIT-TRIAL study group is provided in S1 Supplemental Appendix. * Cedric.Annweiler@chu-angers.fr Accepted: April 26, 2022 Published: May 31, 2022 Copyright: © 2022 Annweiler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit